New Human Biomarker Findings Support Mechanism of Action of Kerendia® (finerenone) in Patients with Chronic Kidney Disease Associated with Type 2 Diabetes
FIGARO-BM, an exploratory human biomarker study, provides additional insight on finerenone’s mechanism of action in blocking mineralocorticoid receptor (MR)... Read more.
Qazi Cosmetic Center Seeks Dismissal of Lawsuit
Points to LOI as nonbinding, unsigned and terminated for unprofessional behavior NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Nadir Qazi, DO, a respected cosmetic... Read more.
Merrimack Reports Third Quarter 2023 Financial Results
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced its third quarter 2023 financial results for the period... Read more.
ATS Corporation Releases FY2023 Sustainability Report
CAMBRIDGE, Ontario–(BUSINESS WIRE)–ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today released its FY2023 Sustainability Report... Read more.
Victory Capital Reports Strong Third Quarter Earnings
Third-Quarter 2023 Highlights Total Assets Under Management (AUM) of $153.5 billion1 Long-term gross flows of $5.3 billion Long-term net flows of ($1.7) billion... Read more.
Energy-Centric AI Acceleration Technology to be Showcased at Super Computing 2023
Untether AI’s CEO to Present: The Need for Energy-Efficient Inference Hardware TORONTO–(BUSINESS WIRE)–#AI—Untether AI®, the leader in energy-centric... Read more.
Continuing a valuable partnership: GDCA Inc. and SMART Embedded Computing extend agreement to provide support for legacy embedded products
LIVERMORE, Calif.–(BUSINESS WIRE)–GDCA Inc., a California-based company that specializes in equipment manufacturing of legacy-embedded computer equipment,... Read more.
Motorola Solutions Reports Third Quarter 2023 Financial Results
Company raises full-year revenue and earnings outlook again Sales of $2.6 billion, up 8% versus a year ago Software and Services sales up 12% Products and Systems... Read more.
Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
Phase 1 monotherapy study of NUV-868 and Phase 1b study of NUV-868 in combination with olaparib or enzalutamide are ongoing Expect to submit an IND for first Drug-Drug... Read more.
Willdan Group Reports Third Quarter 2023 Results
ANAHEIM, Calif.–(BUSINESS WIRE)–$WLDN–Willdan Group, Inc. (“Willdan”) (Nasdaq: WLDN) today reported financial results for its third quarter... Read more.